BYSI BeyondSpring

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate events on June 16, 2021 at 8:30 AM Eastern Time.

The conference call may be accessed by dialing 877-451-6152 (U.S.) or 201-389-0879 (International) and referencing conference ID: 13720525. A live webcast will be available on BeyondSpring’s website at under “Events & Presentations” in the Investors section. An archived replay of the webcast will be available for 90 days.

About BeyondSpring

Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class NDA-stage lead asset plinabulin, a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), is a “pipeline in a drug.” It is filed for approval with Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study (Dublin-3) to test an anti-cancer benefit with an overall survival primary endpoint in non-small cell lung cancer (NSCLC). Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:

Ashley R. Robinson

LifeSci Advisors, LLC



Media Contact:

Darren Opland, Ph.D.

LifeSci Communications





EN
11/06/2021

Underlying

BYSIBeyondSpring

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BeyondSpring

 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Co...

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in , held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism of action and clinical devel...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxe...

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immun...

December 12, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing ...

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in signi...

December 11, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides...

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with MD Anderson collaborators showed DC maturation and M1 macrophage polarization via a Plinabulin specific GEF-H1 dependent mechanism in responding patients with Plinabulin, PD-1 inhibitor and radiation. SEED, co-fou...

November 12, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provide...

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapiesMed (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’s rapid dendritic cell activation in responding patients across eight cancer types who failed prior immunotherapySEED Therapeutics’ RBM39 degrader ST-01156 clears FDA IND and advances toward Phase 1...

August 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch